BCP
TEVA icon

Berylson Capital Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Berylson Capital Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-92,000
Closed -$1.74M – 23
2017
Q4 		$1.74M Buy
+92,000
New +$1.38M 2.68% 18

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Berylson Capital Partners's TEVA Position: Q1 2018 in Review

Berylson Capital Partners sold out of Teva Pharmaceuticals (TEVA) in Q1 2018, closing a stake of 92,000 shares — an estimated $1.74M sold.

Berylson Capital Partners first reported a position in TEVA in Q4 2017 and held it in 1 quarter. The position peaked at $1.74M in Q4 2017. 506 funds tracked by Wall St. Rank hold TEVA as of Q1 2018.

  • Berylson Capital Partners reported no remaining Teva Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Berylson Capital Partners sold 92,000 Teva Pharmaceuticals shares in Q1 2018, an estimated $1.74M.
  • Berylson Capital Partners first reported a position in Teva Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Berylson Capital Partners's Teva Pharmaceuticals position peaked at $1.74M in Q4 2017.
  • 506 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2018.

Based on Berylson Capital Partners's 13F filing for Q1 2018, filed 15 May 2018.